James Crowe
Faculty Member
Last active: 3/31/2019

  1. Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice. Salazar V, Jagger BW, Mongkolsapaya J, Burgomaster KE, Dejnirattisai W, Winkler ES, Fernandez E, Nelson CA, Fremont DH, Pierson TC, Crowe JE, Screaton GR, Diamond MS (2019) Cell Rep 26(6): 1585-1597.e4
    › Primary publication · 30726740 (PubMed) · PMC6420780 (PubMed Central)
  2. A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions. Goo L, Debbink K, Kose N, Sapparapu G, Doyle MP, Wessel AW, Richner JM, Burgomaster KE, Larman BC, Dowd KA, Diamond MS, Crowe JE, Pierson TC (2019) Nat Microbiol 4(1): 71-77
    › Primary publication · 30455471 (PubMed) · PMC6435290 (PubMed Central)
  3. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine. Kimble JB, Malherbe DC, Meyer M, Gunn BM, Karim MM, Ilinykh PA, Iampietro M, Mohamed KS, Negi S, Gilchuk P, Huang K, Wolf YI, Braun W, Crowe JE, Alter G, Bukreyev A (2019) J Virol 93(4)
    › Primary publication · 30518655 (PubMed) · PMC6364037 (PubMed Central)
  4. Antibody Determinants of Influenza Immunity. Crowe JE (2019) J Infect Dis 219(Supplement_1): S21-S29
    › Primary publication · 30715373 (PubMed) · PMC6452307 (PubMed Central)
  5. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE, Bailey JR (2018) Proc Natl Acad Sci U S A 115(1): E82-E91
    › Primary publication · 29255018 (PubMed) · PMC5776832 (PubMed Central)
  6. Structure-function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8. Matho MH, Schlossman A, Gilchuk IM, Miller G, Mikulski Z, Hupfer M, Wang J, Bitra A, Meng X, Xiang Y, Kaever T, Doukov T, Ley K, Crotty S, Peters B, Hsieh-Wilson LC, Crowe JE, Zajonc DM (2018) J Biol Chem 293(1): 390-401
    › Primary publication · 29123031 (PubMed) · PMC5766908 (PubMed Central)
  7. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine. Tsai WY, Chen HL, Tsai JJ, Dejnirattisai W, Jumnainsong A, Mongkolsapaya J, Screaton G, Crowe JE, Wang WK (2018) J Virol 92(23)
    › Primary publication · 30185598 (PubMed) · PMC6232466 (PubMed Central)
  8. Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential for a Universal Influenza Vaccine. Crowe JE (2018) Cold Spring Harb Perspect Biol 10(7)
    › Primary publication · 28663208 (PubMed) · PMC5829045 (PubMed Central)
  9. In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model. Patel A, Park DH, Davis CW, Smith TRF, Leung A, Tierney K, Bryan A, Davidson E, Yu X, Racine T, Reed C, Gorman ME, Wise MC, Elliott STC, Esquivel R, Yan J, Chen J, Muthumani K, Doranz BJ, Saphire EO, Crowe JE, Broderick KE, Kobinger GP, He S, Qiu X, Kobasa D, Humeau L, Sardesai NY, Ahmed R, Weiner DB (2018) Cell Rep 25(7): 1982-1993.e4
    › Primary publication · 30428362 (PubMed) · PMC6319964 (PubMed Central)
  10. Integrating linear optimization with structural modeling to increase HIV neutralization breadth. Sevy AM, Panda S, Crowe JE, Meiler J, Vorobeychik Y (2018) PLoS Comput Biol 14(2): e1005999
    › Primary publication · 29451898 (PubMed) · PMC5833279 (PubMed Central)